CD34 and acute myeloid leukemia: Before addressing the immunophenotypic distinction between APL and “APL-like” NPM1m AML, it is important to note that all of our 77 NPM1m AML cases were indeed CD34-negative as expected, except for 1 case (with a classical NPM1 type A point mutation), which showed moderate expression of CD34 at diagnosis and relapse.